Evidence map›Paper›PMID 38896642›Full record

ArticleBrazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica2024

Rho GTPase activating protein 21-mediated regulation of prostate cancer associated 3 gene in prostate cancer cell.

D A Alves, A F Neves, L Vecchi, T A Souza, E R Vaz, S T S Mota, N Nicolau-Junior, L R Goulart, T G Araújo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

D A AlvesLaboratório de Genética e Biotecnologia, Instituto de Biotecnologia, Universidade Federal de Uberlândia, Patos de Minas, MG, Brasil.ORCID http://orcid.org/0000-0001-9330-1045
A F NevesLaboratório de Biologia Molecular, Universidade Federal de Catalão, Catalão, GO, Brasil.ORCID http://orcid.org/0000-0002-2299-2114
L VecchiLaboratório de Nanobiotechnologia Prof. Dr. Luiz Ricardo Goulart Filho, Instituto de Biotechnologia, Universidade Federal de Uberlândia, Uberlândia, MG, Brasil.ORCID http://orcid.org/0000-0001-8147-0060
T A SouzaLaboratório de Nanobiotechnologia Prof. Dr. Luiz Ricardo Goulart Filho, Instituto de Biotechnologia, Universidade Federal de Uberlândia, Uberlândia, MG, Brasil.ORCID http://orcid.org/0000-0001-6281-1093
E R VazLaboratório de Nanobiotechnologia Prof. Dr. Luiz Ricardo Goulart Filho, Instituto de Biotechnologia, Universidade Federal de Uberlândia, Uberlândia, MG, Brasil.ORCID http://orcid.org/0000-0003-1733-9812
S T S MotaLaboratório de Genética e Biotecnologia, Instituto de Biotecnologia, Universidade Federal de Uberlândia, Patos de Minas, MG, Brasil.ORCID http://orcid.org/0000-0002-2225-4496
N Nicolau-JuniorLaboratório de Modelagem Molecular, Instituto de Biotecnologia, Universidade Federal de Uberlândia, Uberlândia, MG, Brasil.ORCID http://orcid.org/0000-0002-7148-5813
L R GoulartLaboratório de Nanobiotechnologia Prof. Dr. Luiz Ricardo Goulart Filho, Instituto de Biotechnologia, Universidade Federal de Uberlândia, Uberlândia, MG, Brasil.ORCID http://orcid.org/0000-0002-1803-4861
T G AraújoLaboratório de Genética e Biotecnologia, Instituto de Biotecnologia, Universidade Federal de Uberlândia, Patos de Minas, MG, Brasil.ORCID http://orcid.org/0000-0002-7593-1403

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The overexpression of the prostate cancer antigen 3 (PCA3) gene is well-defined as a marker for prostate cancer (PCa) diagnosis. Although widely used in clinical research, PCA3 molecular mechanisms remain unknown. Herein we used phage display technology to identify putative molecules that bind to the promoter region of PCA3 gene and regulate its expression. The most frequent peptide PCA3p1 (80%) was similar to the Rho GTPase activating protein 21 (ARHGAP21) and its binding affinity was confirmed using Phage Bead ELISA. We showed that ARHGAP21 silencing in LNCaP prostate cancer cells decreased PCA3 and androgen receptor (AR) transcriptional levels and increased prune homolog 2 (PRUNE2) coding gene expression, indicating effective involvement of ARHGAP21 in androgen-dependent tumor pathway. Chromatin immunoprecipitation assay confirmed the interaction between PCA3 promoter region and ARHGAP21. This is the first study that described the role of ARHGAP21 in regulating the PCA3 gene under the androgenic pathway, standing out as a new mechanism of gene regulatory control during prostatic oncogenesis.

Indexed as

Antigens, NeoplasmGene Expression Regulation, NeoplasticGTPase-Activating ProteinsProstatic NeoplasmsCell Line, TumorChromatin ImmunoprecipitationEnzyme-Linked Immunosorbent AssayHumansMalePromoter Regions, GeneticReceptors, AndrogenAntigens, NeoplasmGTPase-Activating Proteinsprostate cancer antigen 3, humanReceptors, Androgen

Identifiers

PMID38896642
PMCPMC11186590

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.